eligibility_summary
Inclusion: ≥18, unresectable recurrent/progressive GBM after standard therapy failure/intolerance, OS>2 mo, RANO lesion, tumor ≤2 yrs, CD276+ IHC, KPS≥60, Hb≥90, ANC≥1.5, PLT≥70, CrCl≥60, AST/ALT/Tbili within limits, albumin≥3.0, LVEF≥50, SpO2>95%, contraception/consent. Exclusion: immunosuppression/autoimmune, transplant, unresolved toxicity, uncontrolled effusions, recent steroids/chemo/G‑CSF/radiation/surgery/investigational, CNS risk, prior gene therapy, active HBV/HCV/HIV/syphilis/EBV/CMV, inadequate PD‑1/PD‑L1 washout, major cardiac disease/QTc>480, need anticoagulant/antiplatelet, recent VTE/PE, other malignancy <3y, serious infection, MRI contraindication.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: WL276 (WL276001) CAR-T cells—autologous, gene-modified T lymphocytes expressing a chimeric antigen receptor against CD276 (B7-H3), a cellular immunotherapy/combination product. Mechanism: CAR binding to CD276 redirects T cells to recognize and kill GBM cells independent of native TCR, activating CAR signaling (CD3z plus costimulation), cytokine release, and perforin/granzyme-mediated cytotoxicity. Local intracranial delivery via Ommaya is used to enhance tumor exposure and bypass the BBB. Regimen: weekly dosing x3 at 5x10^6 then 1x10^7 cells (3+3 dose escalation). Targets: CD276/B7-H3 on glioblastoma cells and tumor vasculature, engages T-cell effector pathways, immune synapse formation, and modulates the tumor microenvironment. Population: adults with CD276-positive recurrent/progressive GBM.